Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
01.04. | Peak Bio, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 1 | SEC Filings | ||
06.03. | Akari Therapeutics enters merger deal with Peak Bio | 3 | Pharmaceutical Technology | ||
05.03. | Peak Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
05.03. | Akari Therapeutics rises on all stock deal with Peak Bio | 1 | Seeking Alpha | ||
05.03. | Akari Therapeutics, Peak Bio Announces Agreement To Merge As Equals | - | RTTNews | ||
05.03. | Biotech firms Akari and Peak Bio announce merger | 1 | Investing.com | ||
05.03. | Akari Therapeutics Plc: Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit | 310 | GlobeNewswire (Europe) | BOSTON and PLEASANTON, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory... ► Artikel lesen | |
21.02. | Peak Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
06.02. | Peak Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
29.01. | Peak Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
03.01. | Peak Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
22.12.23 | Peak Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
16.11.23 | Peak Bio, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
02.11.23 | Peak Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
31.08.23 | Peak Bio, Inc., Announces Appointment of Michael Friedman to Board of Directors | 341 | GlobeNewswire (Europe) | Pleasanton, CA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a clinical-stage biopharmaceutical company focused on developing the next-generation... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MORPHOSYS | 65,65 | -3,24 % | ÜBERNAHME-FIEBER bei Biotech-Aktien! Evotec, Bayer, Vidac Pharma - wer folgt auf Morphosys? | Im Biotech-Sektor herrscht Übernahme-Fieber. Zuletzt hat Genmab den Kauf von ProfoundBio, das US-Biotech-Unternehmen entwickelt Medikamente gegen Eierstock- und Gebärmutterschleimhautkrebs, für 1,8... ► Artikel lesen | |
EVOTEC | 9,625 | +4,22 % | Platzt Dienstag die Bombe bei Evotec? Das müssen Aktionäre jetzt dringend beachten, denn sonst ist es zu spät. | ||
QIAGEN | 39,145 | +0,99 % | Minimale Kursveränderung bei Qiagen NV-Aktie (38,75 €) | CODE Der jüngste Kurs betrug 38,75 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Qiagen NV-Aktie. Die Aktie weist aktuell nur einen minimalen Kursabschlag von 0,40 Prozent auf.... ► Artikel lesen | |
JANUX THERAPEUTICS | 56,08 | 0,00 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
SPRINGWORKS THERAPEUTICS | 46,450 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | ||
IMMUNOVANT | 27,490 | 0,00 % | Should You Hold Immunovant (IMVT)? | ||
CABALETTA BIO | 10,480 | 0,00 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
VERA THERAPEUTICS | 41,380 | 0,00 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
NUVALENT | 67,95 | 0,00 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen | |
ARCELLX | 51,11 | 0,00 % | Should You Be Bullish on Arcellx (ACLX)? | ||
CULLINAN THERAPEUTICS | 27,120 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer | CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment... ► Artikel lesen | |
BIONTECH | 83,85 | +1,76 % | DEUTSCHE BANK RESEARCH stuft Biontech auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für das Biotechnologieunternehmen Biontech in einem Ausblick auf den Quartalsbericht mit einem Kursziel von 95 US-Dollar auf... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 8,200 | 0,00 % | Recursion Pharmaceuticals' Options Frenzy: What You Need to Know | ||
BEAM THERAPEUTICS | 22,050 | +3,13 % | Expert Ratings For Beam Therapeutics | ||
ARVINAS | 31,900 | 0,00 % | Arvinas Inc.: Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer | NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today... ► Artikel lesen |